Sun Pharma to buy Organon for $11.75B in major portfolio expansion
Indian drug giant Sun Pharma has lined up an $11.75 billion acquisition of Organon, a women’s health and biosimilar maker spun out of Merck in 2021. The all-cash deal came in at $14 per share ...
An Organon sign seen during the fifth China International Import Expo in 2022 in Shanghai. April 27, 2026 02:16 AM EDT DealsPharma Sun Pharma to buy Organon for $11.75B in major portfolio expansion Kyle LaHucik Biotech Correspondent Indian drug giant Sun Pharma has lined up an $11.75 billion acquisition of Organon, a women’s health and biosimilar maker spun out of Merck in … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that